Advertisement

Clinical Rheumatology

, Volume 37, Issue 4, pp 1059–1064 | Cite as

Prevalence and type II diabetes-associated factors in psoriatic arthritis

  • Rubén Queiro
  • Andrés Lorenzo
  • Estefanía Pardo
  • Anahy Brandy
  • Pablo Coto
  • Javier Ballina
Original Article
  • 171 Downloads

Abstract

Diabetes is a common cardiovascular risk factor in psoriatic arthritis (PsA). Although the prevalence of diabetes is high, the factors associated with it in PsA are poorly understood. We aimed to analyse the prevalence of type II diabetes and diabetes-associated factors in a hospital-based population with PsA. This cross-sectional study included 340 consecutive patients attended in a tertiary care hospital. The prevalence of diabetes was compared to that of 600 outpatients without inflammatory conditions. To analyse diabetes-associated factors, odds ratio (OR) values were calculated by conditional logistic regression analysis. Significant variables in the univariate analysis were then introduced in a multivariate analysis with a backward stepwise approach. Diabetes was more prevalent among PsA patients (13.8 vs. 5%, OR 2.8, 95% CI: 1.7–4.3, p < 0.0001). Diabetes-associated factors in the univariate analysis (p < 0.05) were the following: an age of onset of psoriasis > 40 years, an age of onset of arthritis > 40 years, a low educational level, family history of psoriasis, pustular psoriasis, high number of swollen joints during follow-up, hypertension, dyslipidemia, obesity, and cardiovascular events. After controlling for several confounders, diabetes was significantly associated with late-onset psoriasis (OR 8.2, 95% CI: 1.9–12.4, p = 0.002) and hypertension (OR 7.5, 95% CI: 1.5–13.3, p = 0.008). Diabetes risk should be carefully evaluated in patients with PsA whose psoriasis begins after 40 years.

Keywords

Cardiovascular risk Diabetes Late-onset disease Psoriasis Psoriatic arthritis 

Notes

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am 41:545–568CrossRefGoogle Scholar
  2. 2.
    Husni ME (2015) Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am 41:677–698CrossRefGoogle Scholar
  3. 3.
    Yim KM, Armstrong AW (2017) Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. Rheumatol Int 37:97–105CrossRefPubMedGoogle Scholar
  4. 4.
    Castañeda S, Martín-Martínez MA, González-Juanatey C, Llorca J, García-Yébenes MJ, Pérez-Vicente S, Sánchez-Costa JT, Díaz-Gonzalez F, González-Gay MA, CARMA Project Collaborative Group (2015) Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: baseline data of the CARMA Project. Semin Arthritis Rheum 44:618–626CrossRefPubMedGoogle Scholar
  5. 5.
    Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167–2172PubMedGoogle Scholar
  6. 6.
    Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD (2011) Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res 63:1729–1735CrossRefGoogle Scholar
  7. 7.
    Coto-Segura P, Eiris-Salvado N, González-Lara L, Queiro-Silva R, Martinez-Camblor P, Maldonado-Seral C, García-García B, Palacios-García L, Gomez-Bernal S, Santos-Juanes J, Coto E (2013) Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol 169:783–793CrossRefPubMedGoogle Scholar
  8. 8.
    Queiro R, Tejón P, Alonso S, Coto P (2014) Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology (Oxford) 53:1178–1185CrossRefGoogle Scholar
  9. 9.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRefPubMedGoogle Scholar
  10. 10.
    Rudwaleit M, van der Heijde D, Landewé R et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783CrossRefPubMedGoogle Scholar
  11. 11.
    Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450–456CrossRefPubMedGoogle Scholar
  12. 12.
    Caso F, Del Puente A, Oliviero F et al (2018) Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol.  https://doi.org/10.1007/s10067-017-3975-0
  13. 13.
    Eder L, Chandran V, Gladman DD (2014) The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 73:1990–1996CrossRefPubMedGoogle Scholar
  14. 14.
    Puig L (2018) Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci 19:58.  https://doi.org/10.3390/ijms19010058 CrossRefGoogle Scholar
  15. 15.
    Ding C, Chan Z, Magkos F (2016) Lean, but not healthy: the ‘metabolically obese, normal-weight’ phenotype. Curr Opin Clin Nutr Metab Care 19:408–417CrossRefPubMedGoogle Scholar
  16. 16.
    Odegaard JL, Chawla A (2013) Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339:172–177CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kaur J (2014) A comprehensive review on metabolic syndrome. Cardiol Res Pract 943162Google Scholar
  18. 18.
    Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74:480–489CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ (2014) Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20:500–512CrossRefPubMedGoogle Scholar
  20. 20.
    Allen MH, Ameen H, Veal C, Evans J, Ramrakha-Jones VS, Marsland AM, David Burden A, Griffiths CEM, Trembath RC, Barker JNWN (2005) The major psoriasis susceptibility locus PSORS1 is not a risk factor for late onset psoriasis. J Invest Dermatol 124:103–106CrossRefPubMedGoogle Scholar
  21. 21.
    Queiro R, Coto P (2017) Multidisciplinary care for psoriatic disease: where we are and where we need to go. Rheumatology (Oxford) 56:1829–1831Google Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Rheumatology Division, Department of Internal MedicineHospital Universitario Central de Asturias (HUCA)OviedoSpain
  2. 2.Dermatology Division, Department of Internal MedicineHospital Universitario Central de Asturias (HUCA)OviedoSpain

Personalised recommendations